| Característica |
Objectiu de la convocatòria
The European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) launches its first joint transnational call, focused on explore new treatments to tackle AMR. The aim of the call is to improve treatment success rates in patients, animals, and plants affected by bacterial or fungal infections by providing new therapeutic options while reducing the risk of resistance across different One Health settings.
|
Característiques principals
The proposals must address one of the following topics:
Topic 1: Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
Topic 2: Develop tools and methods to improve adherence to treatment protocols.
Topic 3: Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact:
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: [email protected] Ext.: 1670
Marta López: [email protected] Ext.: 1576
|
Convocatòria (URL)
https://ohamr.eu/funding/funding-opportunities/call-2025-new-treatments-to-tackle-amr/
Submission Platform: https://ptoutline.eu/app/OHAMR2026_OH-TREAT
|
Informació addicional
The call follows a two-step submission procedure (pre-proposals and full proposals).
26 November 2025 (14.00 CET) - Webinar for applicants (registration is needed)
2 February 2026 (13.00 CET) - Deadline for pre-proposals
17 June 2026 (13.00 CEST) - Deadline for full proposals
A partner search tool is available at https://www2.ncn.gov.pl/partners/ohamr-2026/
|
Requisits
Joint proposals may include partners from academia, the clinical/public health sector, enterprises of any size, and operational stakeholders such as patient organisations, municipalities, local governments, and NGOs.
Each partner is funded by its national or regional funding agency, following its own eligibility and financial rules (see National rules and requirements). Investigators from HMRIB must apply for funding to the Instituto de Salud Carlos III (ISCIII).
The consortium must include a minimum of three eligible partners requesting funding from three different eligible countries (including at least two amongst EU Member States or Associated Countries).
The consortium can include a maximum of six project partners (including non-funded partners), which can be increased to seven if includes at least one partner from an under-represented country, at least one Early-Career Researcher PI, or a start-up, SME or industry partner.
A consortium cannot include more than two partners requesting funding from the same funding organisation.
PIs must hold a PhD, may participate in only one project proposal per call, and those affiliated with an IIS must apply exclusively through their IIS.
The same beneficiary institution cannot have more than one PI in the same proposal.
PIs involved in an ongoing JPI AMR PCIN project ending after 31 December 2026 are not eligible unless they serve as coordinator in either the new or ongoing project.
Double funding of the same concept is not allowed; proposals must not overlap with other funded or submitted projects.
Pre-proposals and full proposals must be submitted by the project coordinator on the EUP OHAMR online platform, following the provided templates.
A pre-eligibility form is mandatory: PIs must send their CVA-ISCIII form by email before the pre-proposal submission deadline to [email protected], including the PI’s full name and the proposal acronym in the email subject line.
Spanish research groups conducting a clinical trial are strongly encouraged to include a representative from their SCReN or ECRIN-ERIC node in the team.
Full proposal applicants selected requesting funding from ISCIII must submit a national application.
|
Dotació
Institute of Health Carlos III (ISCIII)
- 220.000 € per project if acting as partner
- 275.000 € per project if acting as partner with other partner
- 300.000 € per project if if acting as coordinator
- 400.000 € per project if acting as coordinator with one additional partner
|
Durada
3 years.
|
AVÍS IMPORTANT
The call is launched at the European level, but each partner is funded by its own national agency and must comply with the corresponding national rules. Due to the call’s complexity, applicants are strongly advised to contact the Research Grants and Contracts Office early and to carefully review the call text and guidelines before starting their application.
|